1. Shepherd PR, Kahn BB: Glucose transporters and insulin action-implications for insulin resistance and diabetes mellitus. N Engl J Med341:248-248, 1999.
2.
2. Taegtmeyer H, McNulty R, Young ME: Adaptation and maladaptation of the heart in diabetes: Part I. General concepts. Circulation105:1727-1727, 2002.
3.
3. Stanley WC, Lopaschuk GD, McCormack JG: Regulation of energy substrate metabolism in the diabetic heart. Cardiovasc Research34:25-25, 1997.
4.
4. Meigs JB: Epidemiology of the metabolic syndrome, 2002. Am J Manag Care8(51):5283-5283, 2002.
5.
5. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel 111). JAMA285:2486-2486, 2001.
6.
6. Howard G, O'Leary DH, Zaccaro D, et al: Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Circulation93:180-917, 1996.
7.
7. Golden SH, Folsom AR, Coresh J, et al: Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: The Atherosclerosis Risk in Communities Study. Diabetes51:3069-3069, 2002.
8.
8. Reusch JE: Current concepts in insulin resistance, type 2 diabetes mellitus, and the metabolic syndromeAm J Cardiol90(SA):19G-19G, 2002.
9.
9. Utriainen T, Takala T, Luotolahti M, et al: Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia41:555-555, 1998.
10.
10. Yokoyama I, Yonekura K, Ohtake T, et al: Role of insulin resistance in heart and skeletal muscle F-18 fluorodeoxyglucose uptake in patents with non-insulin-dependent diabetes mellitus. J Nucl Cardiol7:242-242, 2000.
11.
11. Iozzo P, Chareonthaitawee R, Dutka D, et al: Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes51:3020-3020, 2002.
12.
12. Ungar I, Gilbert M, Siegel A, et al: Studies on myocardial metabolism IV myocardial metabolism in diabetes. Am J Med18:385-385, 1955.
13.
13. Winder WW, Hardie DG: AMP-activated protein kinase, a metabolic master switch: Possible role in type 2 diabetes. Am J Physiol277:E1-E1, 1999.
14.
14. Tian R, Abel ED: Responses of GLUT-4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation103:296-296, 2001.
15.
15. Liao R, Jain M, Cui L, et al: Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation106:2125-2125, 2002.
16.
16. Taegtmeyer H: Switching metabolic genes to build a better heart. Circulation106:2043-2043, 2002.
17.
17. Fath-Ordoubadi F, Beatt KJ: Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: An overview of randomized placebo-controlled trials. Circulation96:1152-1152, 1997.
18.
18. Malmberg K, Norhammar A, Wedel H, Ryden L: Glycometabolic state at admission: Important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation99:262-262, 1999.
19.
19. Van den Berghe G, Wouters FP, Weekers F, et al: Intensive insulin therapy in the critically ill patients. N Engl J Med345:1359-1359, 2001.
20.
20. Stumvoll M, Haring HU. Glitazones: Clinical effects and molecular mechanisms. Ann Med34:217-217, 2002.
21.
21. Fryer LG, Parbu-Patel A, Carling D: The antidiabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem277:25226-25226, 2002.
22.
22. Wayman NS, Hattori Y, McDonald MC, et al. Ligands of the peroxisome proliferator-activated receptors (PPAR-y and PPAR-a) reduce myocardial infarct size. FASEB J16:1027-1027, 2002.
23.
23. Yue T, Chen J, Bao W, et al: In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-y agonist rosiglitazone. Circulation104:2588-2588, 2001.
24.
24. Sidell RJ, Cole MA, Draper NJ, Desrois M, et al: Thiazolidinedione treatment normalizes insulin resistance and ischemia injury in the Zucker fatty rat heart. Diabetes51:1110-1010, 2002.
25.
25. Khandoudi N, Deleriwe R, Berrebi-Bertrand I, et al: Rosiglitazone, a peroxisome proliferator-activated receptor-y inhibits the Jun NH2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/ reperfusion injury. Diabetes51:1507-1507, 2002.
